Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash from Investing Activities (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Cash from Investing Activities for 5 consecutive years, with -$1.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 118.29% year-over-year to -$1.7 million, compared with a TTM value of -$121.7 million through Dec 2025, down 917.42%, and an annual FY2025 reading of -$121.7 million, down 917.42% over the prior year.
  • Cash from Investing Activities was -$1.7 million for Q4 2025 at SAB Biotherapeutics, up from -$129.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $11.2 million in Q2 2024 and bottomed at -$129.9 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is -$7.3 million, with a median of -$365293.0 recorded in 2022.
  • Peak annual rise in Cash from Investing Activities hit 49556.96% in 2024, while the deepest fall reached 147126.32% in 2024.
  • Year by year, Cash from Investing Activities stood at -$2.4 million in 2021, then skyrocketed by 95.01% to -$117754.0 in 2022, then skyrocketed by 42.37% to -$67864.0 in 2023, then soared by 13849.21% to $9.3 million in 2024, then crashed by 118.29% to -$1.7 million in 2025.
  • Business Quant data shows Cash from Investing Activities for SABS at -$1.7 million in Q4 2025, -$129.9 million in Q3 2025, and $5.2 million in Q2 2025.